Public Health Emergency - Leading a Nation Prepared
Urgent care centers can provide monoclonal antibody (mAb) therapy for non-hospitalized patients that have tested positive for COVID-19 and have mild to moderate symptoms. These treatments are indicated for eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or hospitalization.
SPEED supports LTCFs, including nursing homes and assisted living facilities, through partnerships with stakeholder and/or trade associations who assist with educating members and non-members about mAbs. These organizations also identify entities that are able and willing to administer mAbs. Membership in partner associations is not required for participation in SPEED.
SPEED stakeholder/trade association partners include:
If you are considering having your LTCF offer COVID-19 mAb therapy, you can quickly evaluate your readiness in three steps:
Find a more detailed outline of specifics to review when thinking about offering mAb therapy, check out our guide Becoming a Site to Administer COVID-19 mAb Therapy.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages